Treatment of performance status 2 patients with advanced non-small-cell lung cancer: What we know and what we don't know

Future Oncology

Volumn 5, Issue 6, 2009, Pages 837-841

  Tartarone, Alfredo ^a   Aleta, Michele ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

Author keywords

Bevacizumab; Chemotherapy; Erlotinib; Non small cell lung cancer; Paclitaxel poliglumex; PS2 patients; Targeted agents

Indexed keywords

CARBOPLATIN; GEMCITABINE; NAVELBINE; OXALIPLATIN;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; HUMAN; LUNG NON SMALL CELL CANCER; PERFORMANCE STATUS; PRIORITY JOURNAL; RATING SCALE; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; KARNOFSKY PERFORMANCE STATUS; LUNG NEOPLASMS;

EID: 70349202966     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.61     Document Type: Review

References (36)

1. Gridelli C: Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non small cell lung cancer? Lung Cancer 38, S45-S50 (2002).
2. Bunn PA, Lilenbaum R: Chemotherapy for elderly patients with advanced non small cell lung cancer. J. Natl Cancer Inst. 95, 341-343 (2003).
3. Ramsey SD, Howlader N, Etzioni RD et al.: Chemotherapy use, outcomes, and costs for older persons with advanced non small cell lung cancer: evidence from surveillance, epidemiology and end results - medicare. J. Clin. Oncol. 22, 4971-4978 (2004).
4. Extermann M: Measuring comorbidity in older cancer patients. Eur. J. Cancer 36, 453-471 (2000).
5. Birim O, Maat AP, Kappetein AP et al.: Validation of the Charlson comordity index in patients in patients with operated primary non small cell lung cancer. Eur. J. Cardiothorac. Surg. 23, 30-34 (2003).
6. Charlson ME, Pompei P, Ales KL et al.: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chromatic Dis. 40, 373-383 (1987).
7. Asmis TR, Ding K, Seymor L et al.: Age and comorbidity as independent prognostic factors in the treatment of non small cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J. Clin. Oncol. 26, 54-59 (2008).
8. Oken MM, Creech RH, Tormey DC et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5, 649-655 (1982).
9. Jiroutek M, Johnson D, Blum R et al.: Prognostic factors in advanced non small cell lung cancer analysis of Eastern Cooperative Oncology Group trials from 1981-1992. Proc. Am. Soc. Clin. Oncol. 17, 461 (1998) (Abstract 1774).
10. Sweeney CJ, Zhu J, Sandler AB et al.: Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic non small cell lung carcinoma. Cancer 92, 2639-2647 (2001).
11. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311, 899-909 (1995).
12. Gridelli C, Ardizzoni A, Le Chevalier T et al.: Treatment of advanced non small cell lung cancer patients with ECOG performance status 2: results of an European experts panel. Ann. Oncol. 15, 419-426 (2004).
13. Pfister DG, Johnson DH, Azzoli CG et al.: American Society of Clinical Oncology treatment of unresectable non small cell lung cancer guideline: update 2003. J. Clin. Oncol. 22, 330-353 (2004).
14. D'Addario G, Felip E: Non small cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 19 (Suppl. 2), ii39-ii40 (2008).
15. Gridelli C, Perrone F, Gallo C et al.: Chemotherapy for elderly patients with advanced non small cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III randomized trial. J. Natl Cancer Inst. 95, 362-372 (2003).
16. Perrone F, Di Maio M, Gallo C et al.: Outcome of patients with performance status of 2 in the Multicenter Italian Lung Cancer in the elderly Study (MILES). J. Clin. Oncol. 15, 5018-5020 (2004).
17. Lilenbaum RC, Herndon J, List M et al.: Single-agent versus combination chemotherapy. in advanced non small cell lung cancer: the cancer and leukaemia group B (study 9730). J. Clin. Oncol. 23, 190-196, (2005).
18. Kosmidis PA, Dimopoulos MA. Syrigos K et al.: Gemcitabine versus gemcitabine-carboplastin for patients with advanced non small cell lung cancer and a performance status of 2: a prospective randomized Phase II study of the Hellenic Cooperative Oncology Group. J. Thoracic. Oncol. 2, 135-160 (2007).
19. Obasaju CK, Conkling P, Fitzgibbons J et al.: A randomized Phase 3 trial of gemcitabine with or without carboplatin in performance status 2 (PS2) patient with advanced-NSCLC. J. Clin. Oncol. 25(18S) (2007) (Abstract 7533).
20. Lilenbaum R, Villaflor VM, Laager C et al.: Single agent versus combination chemotherapy in patients with advanced non small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J. Thorac. Oncol. 4(7), 869-874 (2009).
21. Mir O, Alexandre J, Ropert S et aal.: Vinorelbine plus oxaliplatin in unfit patients (pts) with stage IV non small cell lung cancer (NSCLC). J. Clin. Oncol. 26(20S) (2008) (Abstract 19064).
22. Hanna N, Shepherd FA, Fossella FV et al.: Randomized Phase III trial of pemetrexed versus docetaxel in patients with non small cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22, 1589-1597 (2004).
23. Scagliotti GV, Parikh P, von Pawel J et al.: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non small cell lung cancer. J. Clin. Oncol. 26, 3543-3551 (2008).
24. Blakely LJ, Schwartzberg L, Keaton M et al.: A Phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non small cell lung cancer. Lung Cancer DOI: 10.1016/j.lungcan.2008.12.017 (2009) (Epub ahead of print).
25. Li C, Newman RA, Wu QP et al.: Biodistribution of paclitaxel and poly(L-glutainic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother. Pharmacol. 46, 416-422 (2000).
26. Singer JW, Shaffer S, Baker B et al.: Paclitaxel poliglumex (Xyotax; CT-2103): an intracellular targeted taxanes. Anticancer Drugs 16, 243-254 (2005).
27. Rose WC, Clark JL, Lee FW et al.: Preclinical antitumor activity of water-soluble paclitaxel derivatives. Cancer Chemother. Pharmacol. 39, 486-492 (1997).
28. Singer JW: Paclitaxel poliglumex (XYOTAX, CT-2103) a macromolecular taxane. J Control Release 109, 120-126 (2005).
29. O'Brien M, Bonomi P, Langer C et al.: Analysis of prognostic factors in chemo-naïve patients with advanced NSCLC and poor performance status (PS): Cox regression analysis of two Phase III trials. J. Clin. Oncol. 24 (18S) (2006) (Abstract 7113).
30. Hesketh PJ, Chansky K, Wozniak AJ et al.: Southwest Oncology Group Phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non small cell lung cancer and a performance status of 2. J. Thorac. Oncol. 3, 1026-1031 (2008).
31. Lilenbaum R, Axerlod R, Thomas S. et al.: Randomized Phase II trial of erlotinib or standard chemotherapy in patients with. advanced non small cell lung cancer and a performance status of 2. J. Clin. Oncol. 26, 863-869 (2008).
32. Lilenbaum R, Wang X, Gu L et al.: Phase II randomized trial of docetaxel plus cetuximab or bortezomib in patients with advanced NSCLC and performance status (PS) 2 CALGB 30402. J. Clin. Oncol. 25(18S) (2007) (Abstract 7595).
33. Gridelli C, Mencoboni M, Carrozza F et al.: Cetuximab (C) and gemcitabine (G) in elderly or adult PS2 advanced non small cell lung cancer (NSCLC) patients (pts): the CALC1 randomized Phase II trials. J. Clin. Oncol. 26(20S) (2008) (Abstract 8117).
34. van Cruijsen H, Giaccone G, Hoeckman K: Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies. Int. J. Cancer 17, 883-888 (2005).
35. Herbst RS, Sandler A: Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. Oncologist 13, 1166-1176 (2008).
36. Wedge SR, Ogilvie DJ, Dukes M et al.: ZD6474 inhibits vascular endothelial growth factor signalling, angiogenesis and tumor growth following oral administration. Cancer Res. 62, 4646-4655 (2002).